Chemotherapy News and Research

Latest Chemotherapy News and Research

Discovery of new gene mutations linked to leukemia

Decoding the complete DNA of cancer patients is giving scientists at Washington University School of Medicine in St. Louis a clearer picture of the complexity of the disease and allowing them to see intriguing and unexpected genetic relationships among patients.

5 Aug 2009

Scientists illuminate brain tumors with fluorescent nanoparticles

Brain cancer is among the deadliest of cancers. It's also one of the hardest to treat. Imaging results are often imprecise because brain cancers are extremely invasive. Surgeons must saw through the skull and safely remove as much of the tumor as they can. Then doctors use radiation or chemotherapy to destroy cancerous cells in the surrounding tissue.

3 Aug 2009

Tarceva shown to extend survival in advanced non-small cell lung cancer when used after initial chemo

OSI Pharmaceuticals, Inc. has announced further results from the Phase III SATURN study showing that Tarceva® (erlotinib) extended the survival of patients with advanced non-small cell lung cancer (NSCLC) when used as single agent, maintenance therapy in patients who did not progress following first-line treatment with platinum-based chemotherapy.

2 Aug 2009

New nano-gene therapy technique could fight late-stage tumors

Tiny particles carrying a killer gene can effectively suppress ovarian tumor growth in mice, according to a team of researchers from MIT and the Lankenau Institute.

31 Jul 2009

Nanoparticles show potential as part of new therapy for advanced ovarian cancer

Nanoparticle delivery of diphtheria toxin-encoding DNA selectively expressed in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect this therapy could be tested in humans within 18 to 24 months, according to a report in Cancer Research, a journal of the American Association for Cancer Research.

30 Jul 2009

Higher drug doses needed to defeat tuberculosis in overweight and obese

The typical dose of a medication considered pivotal in treating tuberculosis effectively is much too low to account for modern-day physiques, UT Southwestern Medical Center researchers said.

30 Jul 2009

Scientists re-engineer human enzyme to become resistant to harmful agents such as chemotherapy

Scientists from the Université de Montréal and McGill University have re-engineered a human enzyme, a protein that accelerates chemical reactions within the human body, to become highly resistant to harmful agents such as chemotherapy, according to a new study published in The Journal of Biological Chemistry.

28 Jul 2009

Cost effectiveness study looks at potential value of new genetic test for guiding chemotherapy treatment

For the 29,000 patients in the United States with metastatic colorectal cancer, chemotherapy with irinotecan is a standard treatment that has been shown to improve survival. But for more than one in 10 of these patients, a variation in their DNA means that this treatment could result in a severe reduction in their white blood cell count, leading to a high risk of bacterial infection and possible subsequent death.

27 Jul 2009

Nanodiamonds hold promise for wound-healing applications

Bacterial infection is a major health threat to patients with severe burns and other kinds of serious wounds such as traumatic bone fractures. Recent studies have identified an important new weapon for fighting infection and healing wounds: insulin.

27 Jul 2009

Surgery after chemotherapy and radiation can be an option for patients advanced lung cancer

In recent years, oncologists have debated whether patients with a certain type of advanced lung cancer would benefit from surgery.

26 Jul 2009

Implantable device offers continuous cancer monitoring

Surgical removal of a tissue sample is now the standard for diagnosing cancer. Such procedures, known as biopsies, are accurate but offer only a snapshot of the tumor at a single moment in time.

21 Jul 2009

Tamoxifen kills fungus cells and may prevent them from causing disease

An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born prematurely and patients with cancer. Some scientists suspected that tamoxifen has antifungal properties; now new research from the University of Rochester Medical Center shows that it actually kills fungus cells and stops them from causing disease.

20 Jul 2009

Nanoparticle Trojan horse for ovarian cancer

In a feat of trickery, Dartmouth Medical School immunologists have devised a Trojan horse to help overcome ovarian cancer, unleashing a surprise killer in the surroundings of a hard-to-treat tumor.

19 Jul 2009

Thalidomide does not improve survival in small cell lung cancer

Treating patients with thalidomide in combination with chemotherapy for small cell lung cancer (SCLC) did not improve their survival but did increase their risk of blood clots, according to a new study published online July 16 in the Journal of the National Cancer Institute.

17 Jul 2009

New discovery on DNA repair mechanism

Researchers at Washington University School of Medicine in St. Louis have shed new light on a process that fixes breaks in the genetic material of the body's cells. Their findings could lead to ways of enhancing chemotherapy drugs that destroy cancer cells by damaging their DNA.

17 Jul 2009

"Drops" of gold that burn tumors

At a technical breakfast, Romain Quidant presented his research into the detection and treatment of cancer using gold nanoparticles illuminated with laser light. Quidant, who was recently awarded the Fresnel Prize 2009 that recognizes the highest level of excellence amongst emerging researchers in the field of photonics, is an ICREA researcher at the UPC's Institute of Photonic Sciences (ICFO) and a fellow of the Cellex Foundation Barcelona.

16 Jul 2009

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Schering-Plough Corporation has announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.

15 Jul 2009

Surprising new insights into the repair strategies of DNA

A microscopic single-celled organism, adapted to survive in some of the harshest environments on earth, could help scientists gain a better understanding of how cancer cells behave.

15 Jul 2009

New brain visualization technology enables removal of fist-sized tumor

A new technology involving the fusion of four different types of images into a 3-D map of a patient's brain has helped University of Cincinnati (UC) specialists successfully remove a fist-sized tumor from the brain of an Indiana woman.

14 Jul 2009

Researchers grow immature egg cells in the laboratory for 30 days - could sustain cancer patients’ fertility

Researchers funded by the National Institutes of Health have completed a critical first step in the eventual development of a technique to retain fertility in women with cancer who require treatments that might otherwise make them unable to have children.

14 Jul 2009